U.S. Markets close in 3 hrs 28 mins

Adlon Therapeutics L.P. and Purdue Pharma L.P. Will Present Data from Adhansia XR™ (methylphenidate HCl) Studies Examining Sleep Quality Outcomes, Functional Outcomes and Executive Functioning at the 2020 APSARD Annual Meeting

Adlon Therapeutics L.P. and Purdue Pharma L.P. will present data from three studies evaluating PRC-063 at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting in Washington D.C. PRC-063 was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older and is currently available as Adhansia XR™ (methylphenidate hydrochloride) extended-release capsules CII.

The Full Prescribing Information for Adhansia XR contains a boxed warning for abuse and dependence. CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines have a high potential for abuse and dependence. Healthcare professionals should assess the risk of abuse prior to prescribing Adhansia XR and monitor for signs of abuse and dependence while patients are on therapy.1

Information from the three posters highlighting the effect of Adhansia XR on sleep quality outcomes in adults and adolescents with ADHD, the effect of Adhansia XR on functional outcomes in adults with ADHD, and the effect of Adhansia XR on executive functioning in adolescents with ADHD is summarized below.

"These studies demonstrate Adlon Therapeutics’ ongoing efforts to inform the scientific community about Adhansia XR following its FDA approval and introduction in 2019," said Mike Ronning, vice president, sales and marketing, and general manager, Adlon Therapeutics. "We are pleased to present relevant medical and disease state studies at this scientific forum."

Adhansia XR is not appropriate for all patients, and healthcare professionals should work with their patients to determine the most appropriate treatment option. Adhansia XR is contraindicated in patients with a known hypersensitivity to methylphenidate or product components, as well as patients receiving concurrent treatment with a monoamine oxidase inhibitor (MAOI) or who have used an MAOI within the preceding 14 days.1

The Full Prescribing Information for Adhansia XR, including Boxed Warning, is available at this link. Please see Important Safety Information for Adhansia XR below, including the Boxed Warning, Contraindications, Warnings and Precautions including the potential for abuse and dependence, serious cardiovascular events, blood pressure and heart rate increases, psychiatric adverse reactions, priapism, peripheral vasculopathy, long-term suppression of growth, allergic-type reactions, and Adverse Reactions.1

Poster #5 (Poster Session 1): Sleep Quality Outcomes in Adults and Adolescents with ADHD Treated with PRC-063 in Two Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studies with Six-Month Open Label Extensions
The Phase 3 program included two randomized, double-blind, placebo-controlled studies and a six-month open-label extension to examine the efficacy and safety of Adhansia XR in adolescent and adult patients with ADHD and assess the effects of Adhansia XR on sleep quality as a secondary endpoint. At screening, baseline, end of double-blind studies, and during monthly open label visits, patients completed the Pittsburgh Sleep Quality Index (PSQI), which is used to measure indicators such as overall sleep quality, sleep latency, duration of sleep, sleep efficiency, sleep disturbances, requiring medication to sleep, and daytime disfunction due to sleepiness.

The studies enrolled 375 adults and 354 adolescents; 333 adults and 323 adolescents completed the double-blind study; 184 adults and 178 adolescents entered the open-label study. In these adult and adolescent studies, patients with a DSM-5 ADHD diagnosis were randomly assigned to a fixed daily dose of Adhansia XR at 25, 45, 70, 85, or 100 mg for four weeks. During a six-month open-label extension, daily doses were titrated to a patient’s optimal dose (25, 35, 45, 55, 70, 85 or 100 mg). The studies evaluated a maximum of 85 mg/day for adolescent patients and 100 mg/day for adult patients.

In the double-blind studies, PSQI Global Scores in adults and adolescents using Adhansia XR remained similar to placebo (Adults: Baseline, 8.8±3.7; End of Double-Blind Placebo, 7.3±4.1; End of Double-Blind Adhansia XR, 8.1±3.6, p=.0972; Adolescents: Baseline, 5.7±3.3; End of Double-Blind Placebo, 5.4±3.7; End of Double-Blind Adhansia XR, 5.4±3.4, p=.6110). During the open-label extension where patients were titrated to their optimum dose, the PSQI Global Scores decreased further from the baseline (Adults: 5.4±3.2, Adolescents: 4.4±3.3). A lower PSQI Global score indicates better sleep quality.

The most common sleep-related adverse events in the double-blind studies were headache (Adults: 17.5%; Adolescents: 15%), insomnia (Adults: 15.8%; Adolescents: 6.5%) and decreased appetite (Adults: 11.1%; Adolescents: 20.1%) In the six month open label continuation, the most frequent adverse events among adults and adolescents were headache (12.9%), insomnia (12.9%), and decreased appetite (11.3%).

Poster #6 (Poster Session 2): Functional Outcomes in Adults with ADHD Treated with PRC-063 in a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study with a Six-Month Open-Label Extension

The randomized, double-blind, fixed-dose study of Adhansia XR and placebo, followed by a six-month open-label extension, sought to identify domain-specific and overall functional improvement in adults with ADHD as a secondary endpoint. The Weiss Functional Impairment Rating Scale (WFIRS), a scale that measures impairment in areas including family, life skills, and social activities, was performed at the beginning of the study, as well as at the end of the double-blind and open-label portions.

The study enrolled 375 adults (≥18 years) with a DSM-5 ADHD diagnosis, of which 333 completed the double-blind portion and 184 entered a six-month open-label extension. Patients were randomly assigned to either a daily dose of Adhansia XR (25, 45, 70 or 100 mg) or placebo. Patients underwent blinded titration to a fixed dose over a two-week period, followed by two weeks at their assigned dose. During the open-label extension, patients were titrated to their optimal dose (25, 35, 45, 55, 70, 85 or 100 mg/day).

During the double-blind portion, WFIRS Total Scores for patients treated with Adhansia XR decreased (least-squares [LS] mean change from baseline [cfb]: -0.24 for Adhansia XR vs. -0.15 for placebo; p=.056), as did specific scores around work (-0.30 for Adhansia XR vs. -0.11 for placebo; p=.01), self-concept (-0.40 for Adhansia XR vs. -0.19 for placebo; p=.04), and risky activities (-0.12 for Adhansia XR vs. -0.04 for placebo; p=.03). A decreased WFIRS score indicates less impairment. These results were seen during the fixed-dose double-blind portion of the study despite approximately 90% of patients being either over or under-dosed. In the open-label portion, on optimized doses, there were significant differences in functional outcomes (p<.0001) across all domains and in the Total Score of the WFIRS.

Adverse effects (AEs) seen in greater than 10% of cases during the double-blind portion included headache (17.5%), insomnia (15.8%), and decreased appetite (11.1%). AEs seen in greater than 10% of cases during the open-label portion included insomnia (15.1%), initial insomnia (11.9%), and headache (10.8%).

Poster #9 (Poster Session 1): Effect of PRC-063 on Executive Functioning in Adolescents with ADHD in a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study with a Six-Month Open Label Extension
The randomized, double-blind, fixed-dose, placebo-controlled study of the clinical efficacy and safety of Adhansia XR, including a six-month open-label extension, assessed executive functioning in adolescents with ADHD as a secondary endpoint. Executive functioning, a mental process that enables individuals to focus attention, remember instructions, and juggle multiple tasks successfully, was evaluated using the Behavior Rating Inventory of Executive Function (BRIEF) at baseline and at the end of both the double-blind and open-label periods.2

Patients randomly assigned to Adhansia XR 25, 45, 70 or 85 mg, or placebo per day underwent two weeks of titration to their fixed dose followed by a two-week assessment period. During six month open-label extension, patients were titrated to their optimal dose (Adhansia XR 25, 35, 45, 55, 70 or 85 mg, or placebo per day). 354 adolescents (12-17 years) with a DSM-5 ADHD diagnosis were enrolled, 323 completed the double-blind study and 178 entered the open-label study.

In the double-blind study, the mean Global Executive Complex (GEC) T-Score (SD) of patients who were randomized to Adhansia XR was 67 (SD 11.57), indicating a change from baseline (cfb) of -6.5. This is in comparison to a mean GEC T-Score of 68.4 (SD 14.1) and cfb of -4 in patients who received placebo (p=.0630). A lower score equals less dysfunction. A greater change was seen during the open-label extension where patients were able to titrate to an optimal dose of Adhansia XR (GEC T-Score: 62.5 [SD 11.75]; p<.0001). These results reached the measure of statistical significance according to the protocol-defined statistical analysis.

The most common adverse events (AEs) during the double-blind study were decreased appetite (16.1%), headache (13.9%), and irritability (8.4%). During the open-label extension, 98% of AEs were mild to moderate in severity and the most common included headache (15.2%), decreased appetite (14.6%), and insomnia (10.7%). Eight patients discontinued treatment during the open-label extension due to an AE.

About Adhansia XR
Adhansia XR was developed by Purdue Pharma (Canada). The medication was granted marketing authorization from Health Canada in December 2017 and is currently marketed in Canada as FOQUEST™ for the treatment of ADHD. In the U.S., the medication was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older in February 2019.

Adhansia XR capsules contain multilayered beads, which are composed of an immediate-release layer which contains approximately 20 percent of the methylphenidate dose, and a controlled-release layer which contains approximately 80 percent of the methylphenidate dose, for oral administration. The MLR™ (multi-layer release) technology is a controlled-release delivery system patented by Purdue Pharma.

Please see Important Safety Information, including Boxed Warning, Warnings & Precautions, and Adverse Reactions below.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.

CONTRAINDICATIONS

Adhansia XR is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Adhansia XR. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other methylphenidate products. Adhansia XR is also contraindicated in patients receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within 14 days following discontinuation of treatment with a MAOI, because of the risk of hypertensive crisis.

WARNINGS AND PRECAUTIONS

Potential for Abuse and Dependence

CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.

Serious Cardiovascular Events

Sudden death, stroke and myocardial infarction have occurred in adults treated with CNS stimulant treatment at recommended doses. Sudden death has occurred in pediatric patients with structural cardiac abnormalities and other serious cardiac problems taking CNS stimulants at recommended doses for ADHD. Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems. Further evaluate patients who develop exertional chest pain, unexplained syncope, or arrhythmias during Adhansia XR treatment.

Blood Pressure and Heart Rate Increases

CNS stimulants cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm). Individuals may have larger increases. Monitor all patients for hypertension and tachycardia.

Psychiatric Adverse Reactions

CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.

CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).

CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. If such symptoms occur, consider discontinuing Adhansia XR. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared to 0% in placebo-treated patients.

Priapism

Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate products, in both pediatric and adult patients. Priapism was not reported with drug initiation but developed after some time on the drug, often subsequent to an increase in dose. Priapism has also appeared during a period of drug withdrawal (drug holidays or during discontinuation). Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.

Peripheral Vasculopathy, including Raynaud’s Phenomenon

CNS stimulants, including Adhansia XR, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of drug. Careful observation for digital changes is necessary during treatment with ADHD stimulants. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.

Long-Term Suppression of Growth

CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.

Careful follow-up of weight and height in pediatric patients ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated pediatric patients (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development.

Closely monitor growth (weight and height) in pediatric patients treated with CNS stimulants, including Adhansia XR. Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.

Allergic-Type Reactions: FD&C Yellow No. 5

Adhansia XR 45 mg capsules contain FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

ADVERSE REACTIONS

The most common (≥5% and twice the rate of placebo) adverse reactions occurring with Adhansia XR in adults are insomnia, dry mouth, and decreased appetite.

The most common (≥5% and twice the rate of placebo) adverse reactions occurring with Adhansia XR in pediatric patients are decreased appetite, insomnia, and weight decreased.

PREGNANCY EXPOSURE REGISTRY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Adhansia XR during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388.

To report SUSPECTED ADVERSE REACTIONS, contact Purdue Pharma L.P. at 1-888-726-7535 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Please read Full Prescribing Information, including Boxed Warning.

About Adlon Therapeutics L.P.
Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders. Our initial focus is on adults and adolescents who have been diagnosed with ADHD. Adlon is a subsidiary of Purdue Pharma L.P. For more information, please visit www.adlontherapeutics.com.

About Purdue Pharma L.P.
Purdue Pharma and its subsidiaries are physician-founded and physician-led companies that develop, manufacture and market medications and consumer health products to meet the evolving needs of healthcare professionals, patients, consumers and caregivers. Purdue Pharma is also committed to supporting national, regional and local collaborations to drive innovations in patient care while continuing our efforts to address the opioid addiction crisis.

Purdue’s subsidiaries include: Adlon Therapeutics L.P., focused on treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders; Avrio Health L.P., a consumer wellness company that provides over-the-counter products to fight infection, promote digestive regularity and support muscle and brain function; Imbrium Therapeutics L.P., established to develop and commercialize non-opioid pain medications and therapies for select oncology and CNS disorders; Rhodes Pharmaceuticals L.P., which develops and supplies primarily solid oral-dose and transdermal medications; Rhodes Technologies, which develops and manufactures active pharmaceutical ingredients; and Greenfield Bioventures L.P., an investment vehicle focused on compounds in the early stages of clinical development.

For more information, visit www.purduepharma.com.

References:

  1. Purdue Pharma L.P. Adhansia XR Full Prescribing Information. May 2019. Accessed January 2020. Retrieved from http://app.adlontherapeutics.com/adhansia-xr/fpi.pdf.
  2. Harvard.edu. Executive Function & Self-Regulation. Accessed January 2020. Retrieved from: https://developingchild.harvard.edu/science/key-concepts/executive-function/.

MR-06474

View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005155/en/

Contacts

Media Contacts:

media@adlontherapeutics.com

media@pharma.com

  • ‘Taxpayers are leaving millions of dollars off their returns.’ Why Americans repeatedly overlook this lucrative tax credit
    Business
    MarketWatch

    ‘Taxpayers are leaving millions of dollars off their returns.’ Why Americans repeatedly overlook this lucrative tax credit

    Some 44% possibly eligible for the credit — by making less than $40,000 a year — were not aware of it, according to a new survey from the tax preparation company Jackson Hewitt. More than half of the same group either said they did not qualify (20%) or didn't know if they qualified (33%), according to the survey. The results reinforce past research on lagging claim rates for a program that was started 45 years ago.

  • I’m 38 with $315,000 saved for retirement, but have $30,000 in debt. Should I lower my 401(k) contributions to get rid of that debt?
    Business
    MarketWatch

    I’m 38 with $315,000 saved for retirement, but have $30,000 in debt. Should I lower my 401(k) contributions to get rid of that debt?

    Dear Catey, I currently have about $315,000 in retirement savings and am 38 years old. I have about $30,000 in consumer debt (this is the only debt we carry, no car payment or mortgage) — about $24,000 of which is an unsecured loan that I'm paying about 10% interest on; the rest is on credit cards that are on a 0% promotional period and that I hopefully pay off before the 0% period expires in October 2020. I'm trying to pay down my debt and continue to save aggressively for retirement…I've made minimal improvements over the past couple of years paying down my debt and continue to play the balance transfer game on credit cards to retain 0% interest rates or other low rate options.

  • Tesla Stock Surge Continues With Fourth-Quarter Earnings Coming Up
    Business
    Investor's Business Daily

    Tesla Stock Surge Continues With Fourth-Quarter Earnings Coming Up

    Tesla stock shot up to a record high Wednesday as the electric-car company reached a market valuation above $100 billion for the first time and gets set to report fourth-quarter earnings next week. Tesla overtook Volkswagen as the second most valuable auto company. The market cap of Tesla, at about $105 billion, is above General Motors and Ford Motor combined.

  • Business
    GuruFocus.com

    Buy AT&T for the Free Cash Flow and Possible Multiple Expansion

    AT&T Inc. (NYSE:T) is one of the most well-known stocks among dividend growth investors. With a yield above 5%, AT&T is also one of the highest yielding stocks in the S&P 500 index. The company has more than three decades of dividend growth, qualifying it as a Dividend Aristocrat.

  • Business
    Benzinga

    8 Stocks To Buy With Dividend Yields Of At Least 9%

    Fortunately, there are plenty of stocks out there with generous dividend or distributions yields that analysts see as good investments as well. Here are eight stocks to buy with at least 9% yields, according to Bank of America. TCG is a business development company, a type of closed-end investment company that invests in small and mid-sized businesses.

  • New FDA documents shed light on agency's rejection of Sarepta drug
    Business
    American City Business Journals

    New FDA documents shed light on agency's rejection of Sarepta drug

    Patient deaths, testing concerns and “weak arguments.” Those are just a few of the issues the FDA had with Sarepta Therapeutics's recent drug application, according to new documents released this week. The FDA offered a rare peek at its decision-making process Wednesday, releasing documents related to its initial rejection and later approval of Sarepta's (Nasdaq: SRPT) rare disease drug Vyondys 53. An FDA spokesperson did not immediately respond when asked why the agency released the letters.

  • AT&T Finds a New Way to Help Grind Down Its Debt Mountain
    Business
    Bloomberg

    AT&T Finds a New Way to Help Grind Down Its Debt Mountain

    While that's a higher interest rate than nearly any loan AT&T could have received, the one significant advantage is that the $6 billion doesn't add to its $165 billion debt pile. This is a bit of a surprise for a high-grade-debt company like AT&T,” said Dave Novosel, an analyst with Gimme Credit. AT&T representatives declined to comment on the tower-receivables entity, citing a quiet period ahead of its earnings report later this month.

  • Bernie Sanders Reacts to Hillary Clinton's Comments Saying 'Nobody Likes Him'
    Politics
    Meredith Videos

    Bernie Sanders Reacts to Hillary Clinton's Comments Saying 'Nobody Likes Him'

    Hillary Clinton says “nobody likes” her former presidential rival Bernie Sanders, even as the Vermont senator remains entrenched among the front-runners in the Democratic race

  • Should You Buy Nokia Corporation (HEL:NOKIA) For Its Dividend?
    Business
    Simply Wall St.

    Should You Buy Nokia Corporation (HEL:NOKIA) For Its Dividend?

    Dividend paying stocks like Nokia Corporation (HEL:NOKIA) tend to be popular with investors, and for good reason - some research suggests a significant amount of all stock market returns come from reinvested dividends. Before you buy any stock for its dividend however, you should always remember Warren Buffett's two rules: 1) Don't lose money, and 2) Remember rule #1. Explore this interactive chart for our latest analysis on Nokia!

  • JPMorgan: 3 High-Yield Dividend Stocks to Snap Up Now
    Business
    TipRanks

    JPMorgan: 3 High-Yield Dividend Stocks to Snap Up Now

    It's not that they are necessarily incompatible – rather, it is just that the highest growth stocks tend to achieve their appreciation by plowing profits directly back into the company. The natural place to look is in sectors with high cash flows and essential products. Investment bank JPMorgan released a special report on the North American energy industry, emphasizing just these attributes – the rising production, the high cash flow, and the fundamental strength of the industry to survive a prolonged period of low prices.

  • Exxon Mobil Corporation’s (NYSE:XOM) Investment Returns Are Lagging Its Industry
    Business
    Simply Wall St.

    Exxon Mobil Corporation’s (NYSE:XOM) Investment Returns Are Lagging Its Industry

    Today we are going to look at Exxon Mobil Corporation (NYSE:XOM) to see whether it might be an attractive investment prospect. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. First, we'll go over how we calculate ROCE.

  • Should You Worry About MannKind Corporation's (NASDAQ:MNKD) CEO Pay?
    Business
    Simply Wall St.

    Should You Worry About MannKind Corporation's (NASDAQ:MNKD) CEO Pay?

    In 2017 Michael Castagna was appointed CEO of MannKind Corporation (NASDAQ:MNKD). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. At the time of writing, our data says that MannKind Corporation has a market cap of US$352m, and reported total annual CEO compensation of US$1.5m for the year to December 2018.

  • How 5 of America's Richest Families Lost It All
    Business
    MoneyWise

    How 5 of America's Richest Families Lost It All

    Some of America's oldest family fortunes were built in the 1800s, during the nation's rocky but formative youth. The Rockefellers grew wealthy after John D. Rockefeller struck oil, and Levi Strauss got rich after inventing blue jeans as work pants for the Gold Rush days. Such losses -- which can happen in just one generation or stretch out over a century or longer -- are often driven by bad decisions, such as overspending and debt; investments that didn't pan out; and family infighting over the money.

  • Is Exact Sciences Corporation (NASDAQ:EXAS) Trading At A 40% Discount?
    Business
    Simply Wall St.

    Is Exact Sciences Corporation (NASDAQ:EXAS) Trading At A 40% Discount?

    How far off is Exact Sciences Corporation (NASDAQ:EXAS) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's value. This is done using the Discounted Cash Flow (DCF) model.

  • Head of U.S.’ largest bank says central banks are fueling a sovereign debt bubble, negative-rates won’t ‘end well’
    Business
    MarketWatch

    Head of U.S.’ largest bank says central banks are fueling a sovereign debt bubble, negative-rates won’t ‘end well’

    Jamie Dimon doesn't have much positive to say about negative interest rates in Europe and Japan or public policy in the United States during the past decade. The JPMorgan Chase & Co. (JPM) Chairman and CEO blasted the policy of negative interest rates adopted in Europe and Japan during an interview Wednesday with CNBC, while arguing that economic growth in the U.S. could have been nearly double its actual rate if the government policy had been better. Dimon took aim at fiscal and other economic policies in place at the U.S. federal level.

  • Wiping out the nation’s student-loan debt could have unintended financial consequences for borrowers
    Business
    MarketWatch

    Wiping out the nation’s student-loan debt could have unintended financial consequences for borrowers

    Here are some of the ways student-loan forgiveness could affect borrowers' finances: Student-debt cancellation would raise tax bills under existing rules A cancelled loan means people no longer have to pay a lender, but current IRS rules say borrowers — with certain exceptions for scammed students, permanently disabled veterans and public-sector workers — still have to pay the tax authority before they can get out from under a student loan. Take a hypothetical borrower who owes almost $18,000. That's the median student-loan balance for all borrowers, according to the Federal Reserve Bank of New York.

  • Jumia, Africa's 'Amazon', seeks to move on from a bruising 2019
    Business
    Reuters Videos

    Jumia, Africa's 'Amazon', seeks to move on from a bruising 2019

    Jumia Technologies will focus on proving it can turn a profit after a bruising 2019, one of the e-commerce giant's co-founders - Jeremy Hodara - has said. SOUNDBITE) (English) CO-CHIEF AND EXECUTIVE AND FOUNDER, JEREMY HODARA SAYING: "Now we're going to be extremely disciplined and very focused on our path to profitability, and that's where we are going." Africa's first tech company to list in New York hit a peak value of close to $4 bln, but has seen its shares fall by nearly 70% since its initial public offering in April.

  • Occidental Petroleum eyes sequestering Colorado cement mine's CO2 to help oil production
    Business
    American City Business Journals

    Occidental Petroleum eyes sequestering Colorado cement mine's CO2 to help oil production

    An offshoot of Occidental Petroleum may try a large-scale carbon sequestration project taking carbon dioxide from a southern Colorado cement plant and injecting it under West Texas oilfields to boost oil yields there. The pilot could make both cement production and oil wells more climate-friendly. It could also prompt carbon sequestration projects to spread north to other parts of Colorado and southern Wyoming.

  • Toyota to recall 3.4 million vehicles worldwide, air bags may not deploy in crashes
    Business
    Reuters

    Toyota to recall 3.4 million vehicles worldwide, air bags may not deploy in crashes

    Toyota Motor Corp said on Tuesday it will recall 3.4 million vehicles worldwide because of an electronic defect that can result in air bags not deploying in crashes. The recall, which includes 2.9 million U.S. vehicles, covers 2011-2019 Corolla, 2011-2013 Matrix, 2012-2018 Avalon and 2013-2018 Avalon Hybrid vehicles and is tied to a report of one fatal crash. The vehicles may have an electronic control unit that does not have adequate protection against electrical noise that can occur in crashes, which could lead to incomplete or non-deployment of the air bags.

  • Business
    MarketWatch

    FuelCell's stock tumbles after wider-than-expected loss, revenue missed forecasts

    Shares of FuelCell Energy Inc. fcel) plunged 23% on heavy volume in premarket trading Wednesday, after the fuel cell technology company reported a wider-than-expected fiscal fourth-quarter loss and revenue that fell more than forecast. Trading volume was 10.4 million shares, making the stock the most actively traded ahead of the open.

  • The stock market is on steroids and it could end up like the dot com bubble: top money manager
    Business
    Yahoo Finance

    The stock market is on steroids and it could end up like the dot com bubble: top money manager

    Skybridge Capital co-CIO Troy Gayeski makes a hell of a lot of sense to this journalist pounding the pavement in Davos at the World Economic Forum. It's because Gayeski's (who is an upbeat guy by nature based on our interactions in the past) take on the markets is rationale and appears to be where we are headed thanks to a helping hand of interest rate cuts from the Federal Reserve. Gayeski is quick to point out that the Fed slashed interest rates three times and expanded its balance sheet in 1998.

  • Is It Time to Buy These 3 Beaten-Down Stocks? Analysts Say Yes
    Business
    TipRanks

    Is It Time to Buy These 3 Beaten-Down Stocks? Analysts Say Yes

    The term 'buy when there's blood in the streets' was coined in the 18th century by Baron Rothchild. While some investors automatically avoid underperforming names, the ones willing to take the risk can often receive handsome reward once the company at question executes a turnaround. With this in mind, We'll open up the TipRanks database and take a look at three beaten down stock which those in the know think are ripe for a trend reversal.

  • Amazon hits $200 billion mark beating Google and Apple to become world’s most valuable brand
    Business
    MarketWatch

    Amazon hits $200 billion mark beating Google and Apple to become world’s most valuable brand

    Amazon (AMZN)  has beaten Google (GOOG) Apple (AAPL) and Microsoft (MSFT) to become the world's most valuable brand, according to a global report. The value of the e-commerce giant's brand has soared 17.5% to a record $220.8 billion - the first brand to top $200 billion - the Brand Finance Global 500 index found. Google, which comes second, also climbed in value, while third-placed Apple and fourth-placed Microsoft saw their brand values dip.

  • Goldman Sachs's CEO just called WeWork's pulled IPO -- which Goldman was underwriting -- proof that the market works
    Business
    TechCrunch

    Goldman Sachs's CEO just called WeWork's pulled IPO -- which Goldman was underwriting -- proof that the market works

    It's hard to put a positive spin on a terrible situation, but that didn't stop Goldman Sachs CEO David Solomon earlier today. Asked during a session at the World Economic Forum in Davos about WeWork's yanked IPO in September, Solomon suggested it was proof that the listing process works, despite that the CFO of Goldman -- one of the offering's underwriters -- disclosed last fall that the pulled deal cost the bank a whopping $80 million. Reuters was on the scene, reporting that Solomon acknowledged the process was “not as pretty as everybody would like it to be," while also eschewing any responsibility, telling those gathered that the "banks were not valuing [WeWork].

  • Business
    Barrons.com

    Here’s How to Know When the Stock Rally Is Over

    The Fed's low interest rates and optimism about global economic growth after the U.S.-China phase one trade deal are the two main pillars driving the recent stock market rally, Tom Essaye, founder of Sevens Report Research, wrote in a note on Tuesday. The growth has proven largely immune to potential market shocks, such as the targeted killing of Iranian Maj. Gen. Qassem Soleimani on Jan. 3 and Pres. According to Sevens Report, the two factors that could reverse the upward trajectory of valuations would be stalling economic growth and higher interest rates.